LWM
ALDX icon

Laidlaw Wealth Management’s Aldeyra Therapeutics ALDX Stock Holding History

Laidlaw Wealth Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,175
Closed -$90.7K – 60
2024
Q4 		$90.7K Hold
18,175
– – 0.04% 172
2024
Q3 		$98K Buy
18,175
+1,300
+8% +$6.19K 0.05% 170
2024
Q2 		$55.9K Buy
16,875
+4,150
+33% +$16.3K 0.03% 169
2024
Q1 		$41.6K Buy
+12,725
New +$41.9K 0.02% 170
2023
Q2 		– Sell
-18,000
Closed -$179K – 352
2023
Q1 		$179K Hold
18,000
– – 0.04% 340
2022
Q4 		$125K Buy
+18,000
New +$103K 0.03% 344

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Laidlaw Wealth Management's ALDX Position: Q1 2025 in Review

Laidlaw Wealth Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2025, closing a stake of 18,175 shares — an estimated $90.7K sold.

Laidlaw Wealth Management first reported a position in ALDX in Q4 2022 and held it in 6 quarters. The position peaked at $179K in Q1 2023. 125 funds tracked by Wall St. Rank hold ALDX as of Q1 2025.

  • Laidlaw Wealth Management reported no remaining Aldeyra Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Laidlaw Wealth Management sold 18,175 Aldeyra Therapeutics shares in Q1 2025, an estimated $90.7K.
  • Laidlaw Wealth Management first reported a position in Aldeyra Therapeutics in Q4 2022 and held it in 6 quarters.
  • Laidlaw Wealth Management's Aldeyra Therapeutics position peaked at $179K in Q1 2023.
  • 125 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2025.

Based on Laidlaw Wealth Management's 13F filing for Q1 2025, filed 16 May 2025.